Introduction
The centrosomes play a key role in the establishment of bipolar spindles during mitosis as core components of spindle poles. As chromosomes are pulled toward each spindle pole, the formation of bipolar spindles is essential for accurate chromosome segregation. Upon cytokinesis, each daughter cell receives only one centrosome, and thus centrosomes, like DNA, duplicate once in each cell cycle. Therefore, at any given time point, a cell has either one or two centrosomes, and numeral homeostasis of centrosomes must be maintained. The presence of more than two centrosomes (centrosome amplification) increases the frequency of mitotic defect and unbalanced chromosome segregation. Indeed, centrosome amplification is frequently found in cancer cells, and occurrence of centrosome amplification is strongly associated with chromosome instability (reviewed by D' Assoro et al., 2002; Fukasawa, 2005) . Generation of amplified centrosomes is primarily caused by deregulated duplication of centrosomes. Centrosome duplication proceeds in coordination with other cell cycle events (i.e., DNA replication), normally starting at the time of S phase entry and being completed in late G2 phase (Mazia, 1987) . Thus, it is not surprising that the pathways controlling initiation of DNA synthesis are also involved in the regulation of centrosome duplication. For instance, cyclin-dependent kinase 2 (CDK2)/cyclin E, a key initiator of DNA replication (reviewed by Heichman and Roberts, 1994; Sherr, 1994) , triggers centrosome duplication (reviewed by Hinchcliffe and Sluder, 2002) . Accordingly, p53 is also involved in the regulation of centrosome duplication (reviewed by Tarapore and Fukasawa, 2002) . p21
Waf1/Cip1 (p21), a potent inhibitor of CDK and a major transactivation target of p53 (El-Deiry et al., 1993; Harper et al., 1993; Xiong et al., 1993) , is expressed constitutively at a basal level throughout the cell cycle in a p53-dependent manner, which restrain untimely activation of CDK2/ cyclin E (Tang et al., 1998 , Mussman et al., 2000 Minella et al., 2002) , and thus preventing untimely initiation of centrosome duplication. In addition, cycling cells under any given environment (either in vitro or in vivo) are subjected to internal as well as external stress that temporarily halts DNA synthesis. Under such condition, p53 becomes stabilized, leading to the upregulation of p21, which in turn suppresses the CDK2 activity, and thus inhibiting centrosome duplication (maintaining the coupling of centrosome duplication and DNA replication) until the stress is relieved (Kawamura et al., 2004) . Another transactivation target of p53 in respect to numeral homeostasis of centrosomes is BubR1 spindle checkpoint protein.
Spindle defects caused by amplified centrosomes triggers BubR1-dependent mitotic catastrophe and cell death, which efficiently eliminate cells that have acquired extra centrosomes from the population. In the absence of p53, BubR1 expression level is minimal, weakening the checkpoint response to mitotic defects associated with amplified centrosomes, which allows the persistence of cells with amplified centrosomes (Oikawa et al., 2005) . Thus, p53 heavily depends on its transcriptional activity to regulate centrosome duplication and numeral homeostasis of centrosomes. However, numerous studies have shown that p53 localizes to centrosomes (Blair Zajdel and Blair, 1988; Brown et al., 1994; Morris et al., 2000; Ciciarello et al., 2001; Tarapore et al., 2001b) . Because the centrosome is a non-membranous organelle, any cytoplasmic proteins can rather freely access to this organelle. Thus, the proteins found at centrosomes do not necessarily participate in the centrosome function and/or duplication, and there had been no direct demonstration for the role of the centrosomally localized p53 in the regulation of centrosome duplication. Here, we identified the naturally occurring as well as experimentally generated missense p53 mutations, which are either transactivation function( þ )/centrosome-binding(À) or transactivation function(À)/centrosome-binding( þ ), and tested their abilities to regulate centrosome duplication. We found that both transactivation function and centrosome binding activity are required for p53 to control centrosome duplication at a maximal level, providing the direct evidence of the role of the centrosomally localized p53 in the regulation of centrosome duplication.
Results and discussion
Identification of the transactivation function-positive and centrosome-binding-negative p53 missense mutation We have previously shown that some p53 missense mutants found in tumors retain the centrosome-binding activity, whereas some no longer possess such activity (Tarapore et al., 2001b) . In contrast, the majority of p53 missense mutations found in tumors inactivate the transactivation function. To test directly whether the centrosomally localized p53 participates in the regulation of centrosome duplication, it is necessary to identify the missense mutation that does not affect the p53s transactivation function, but abolishes its ability to localize at centrosomes. It has been shown that p53 has two leucine-rich nuclear export signal (NES) located at the N terminus (amino-acid (a.a.) 13-30 in mouse p53) (Zhang and Xiong, 2001) and at the C terminus (a.a. 337-348) (Stommel et al., 1999) . As centrosomes are present in the cytoplasm, we tested whether the NES mutation abrogates the ability of p53 to localize to centrosomes. The C-terminal NES resides within the tetramerization domain, and mutations in this NES disrupt the ability of p53 to tetramerize (Stommel et al., 1999) . As tetramerization is important for p53 to fully exert its transactivation function (reviewed by Woods and Vousden, 2001) , we decided to introduce point mutations in the N-terminal NES at two leucine residues (L13-A and L17-A). We first examined whether the p53L13A/L17A mutant retains the transactivation function. p53 À/À mouse embryonic fibroblasts (MEFs) were transfected with either a plasmid encoding p53L13A/L17A or a vector control. Wild-type p53 (positive control) and p53D278N transactivation mutant (negative control) were also transfected. The lysates prepared from the transfectants were immunoblotted for p53 as well as p21, a major transactivation target of p53 ( Figure 1 ). For immunoblot analysis, the lysates from p53
MEFs were included as a reference. The p53D278N transactivation(À) mutant was expressed more efficiently (lane 4, top panel) than wild-type p53 (lane 3, top panel), which was expected from the fact that cellular toxicity associated with p53 overexpression is alleviated by the loss of the transactivation function. Indeed, p53D278N almost completely lost the ability to induce p21 expression (lane 4, second panel). In contrast, the p53L13A/L17A mutant induced p21 expression as efficiently as wild-type p53 (lane 9, second panel), indicating that the p53L13A/L17A mutant retains its transactivation function. We also tested whether introduction of D278N mutation into the p53L13A/L17A mutant abrogates the transactivation function. As expected, the p53L13A/L17A/D278N mutant failed to upregulate p21 (lane 10, second panel). À/À MEFs (passage 8) were transiently transfected with a mammalian expression plasmid encoding mouse wild-type p53, p53D278N, p53L13A/L17A, or p53L13A/L17A/D278N using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). The transfection efficiency is >40% using this reagent. As a control, the vector plasmid was transfected. The cell lysates were prepared from the transfectants at 24 h posttransfection as well as from untransfected p53 þ / þ MEFs (passage 4) and p53 À/À MEFs, and immunoblotted with anti-p53 (FL-393, Santa Cruz Biotech, Santa Cruz, CA, USA), anti-p21 (F-5, Santa Cruz Biotech) or anti-a-tubulin (loading control, DM1A, Sigma, Immunochemicals, St Louis, MO, USA) antibodies as described previously (Shinmura et al., 2005) .
We next examined the ability of the p53L13A/L17A mutant to localize to centrosomes. FLAG-tagged wildtype p53, p53D278N and p53L13A/L17A were transfected into p53 À/À MEFs. The vector plasmid was transfected as a control. The transfected cells were briefly extracted before fixation, and co-immunostained with anti-g-tubulin (a major component of centrosomes, reviewed by Joshi, 1994; Oakley, 2000) and either antip53 (Figure 2A ) or anti-FLAG antibodies ( Figure 2B ). Wild-type p53 was readily detected at both unduplicated and duplicated centrosomes (panels b1-4 and c1-4). The D278N transactivation mutant was also found at both unduplicated and duplicated centrosomes (panels d1-4, e1-4). In contrast, the p53L13A/L17A mutant failed to localize to both unduplicated and duplicated centrosomes (panels f1-4, g1-4). Thus, we successfully identified a missense mutant p53 that retains its transactivation function, but has lost the ability to localize to centrosomes (or is reduced for its centrosome-binding activity to the level undetectable by immunocytochemistry). We also tested the centrosome-binding activity of the p53L13A/L17A/D278N mutant, and found that it failed to localize to centrosomes as expected (data not shown). À/À MEFs were transiently transfected with a plasmid encoding FLAG-tagged wild-type p53, p53D278N, or p53L13A/L17A. As a control, the vector plasmid was transfected. At 24 h post-transfection, the cells were briefly extracted (10 s) with extraction buffer (0.75% Triton X-100 in PBS), followed by wash with PBS, and fixed in 10% formalin/10% methanol. The cells were first incubated with blocking solution (10% normal goat serum in PBS) for 1 h, and then probed with mouse anti-g-tubulin (GTU-88, Sigma, Immunochemicals) and rabbit anti-p53 antibodies for 1 h. The antibody-antigen complexes were detected with Alexa Fluor 488-conjugated goat anti-mouse IgG and Alexa Fluor 546-conjugated goat anti-rabbit IgG antibodies (Molecular Probes, Eugene, OR, USA). The cells were washed with PBS after each incubation, and counterstained for DNA with 4 0 , 6-diamidino-2-phenylindole (DAPI). Cells were examined under a fluorescence microscope (Nikon Microphot-FX) using a Â 60 objective lens. The fluorescence images were captured with SPOT CCD camera (Diagnostic Instruments Inc., Sterling Heights, MI, USA). Scale bar, 10 mm. (B) The transfected cells described in (a) were also co-immunostained with rabbit anti-g-tubulin and mouse anti-FLAG (M2, Sigma) antibodies, and the antibody-antigen complexes were detected with Alexa Fluor 594-conjugated goat anti-mouse IgG and Alexa Fluor 488-conjugated goat anti-rabbit IgG antibodies. Cells were also stained with DAPI. Scale bar, 10 mm. For both A and B, the arrows point to the positions of centrosomes, and the insets show the magnified images of the areas indicated by arrows.
Role of centrosomally localized p53 in the regulation of centrosome duplication
To test the p53L13A/L17A mutant for its activity to control centrosome duplication, we performed a centrosome re-duplication assay. This assay was developed by the fact that in cells arrested at late G1, G1/S transition or S phase by exposure to DNA synthesis inhibitors (i.e., hydroxyurea, aphidicolin, actinomycin D, 5-bromo deoxyuridine) or inhibitors of S phase entry (i.e., mimosine), centrosomes continue to duplicate in the absence of DNA synthesis, resulting in generation of amplified (X3) centrosomes (Balczon et al., 1995; Tarapore et al., 2001a; Bennett et al., 2004 ) (see the experimental scheme shown in Figure 3b ). However, because of the negative regulation of centrosome duplication by p53, centrosome re-duplication in the arrested cells occurs preferentially in the absence of p53 (i.e., p53 À/À MEFs) (Tarapore and Fukasawa, 2002) . We have previously shown that centrosome re-duplication is significantly suppressed in p53 À/À MEFs when wild-type p53 is exogenously introduced (Tarapore et al., 2001a) . Using this finding as a model system, we tested the centrosome re-duplication suppressing activity of the p53L13A/L17A mutant. As a negative control, we used the p53L13A/L17A/D278N transactivation(À)/centrosome-binding(À) double mutant p53. The transactivation functions and centrosome-binding activities of wildtype p53, p53D278N, p53L13A/L17A and p53L13A/ L17A/D278N are summarized in Figure 3a . Wild-type p53, p53D278N, p53L13A/L17A and p53L13A/L17A/ D278N as well as a vector control were co-transfected with a plasmid encoding green fluorescent protein (GFP)-tagged histone 2B (H2B-GFP) as a transfection marker. Twelve hours later, mimosine was added to the media, and cells were cultured for 40 h (Figure 3b ). The transfected cells were then fixed and the GFP-positive cells were examined for their centrosome profiles by immunostaining for g-tubulin (Figure 3c ). In early-midpassage (passage 8) p53
À/À MEFs, 20-40% of cells contain amplified centrosomes owing to the combination of continuous generation of amplified centrosomes owing to de-regulated centrosome duplication and continuous elimination of cells with amplified centrosomes during mitosis owing to mitotic defects associated with centrosome amplification (Oikawa et al., 2005) . Indeed, B20% of the p53 À/À MEFs used in this study before transfection and mimosine treatment contained amplified centrosomes (Figure 3c, column 1) . When cells were exposed to mimosine for 40 h, the frequency of centrosome amplification increased to B55% (column 2). A similar frequency of centrosome amplification was observed in the vector-transfected control cells (column 3). It should be noted here that it has previously been shown that centrosomes do not re-duplicate in cells during mimosine-induced arrest (Matsumoto et al., 1999) . The discrepancy may likely reflect the different cell types used in the studies. It has been known that in mouse cells (MEFs), loss of p53 leads to promiscuous activation of CDK2/cyclin E to the level sufficient for triggering centrosome re-duplication when the cell cycle is halted, even at the cell cycle stage in which CDK2/ cyclin E is not normally activated (Mussman et al., 2000) . As shown previously (Tarapore et al., 2001a) , centrosome re-duplication during mimosine-induced arrest is significantly suppressed in the wild-type p53-transfected cells (B25%, column 4). The transactivation(À) mutant (p53D278N) and centrosomebinding(À) mutant (p53L13A/L17A) both suppressed centrosome re-duplication, but much less efficiently (B35%, columns 5 and 6, respectively) than wild-type p53, suggesting that both transactivation function and centrosome localization are required for p53 to fully control centrosome duplication. Indeed, the transactivation(À)/centrosome-binding(À) double mutant (p53L13A/L17A/D278N) failed to suppress centrosome re-duplication (B50%, column 7). Moreover, coexpression of p53L13A/L17A and p53D278N mutants À/À MEFs (passage 8) were transfected with a FLAG-vector, FLAG-tagged wild-type p53, p53D278N, p53L13A/ L17A, p53L13A/L17A/D278N, or p53D278N þ p53L13A/L17A. A plasmid encoding H2B-GFP was co-transfected as a transfection marker at 15:1 molar ratio. The transfected cells were subjected to the centrosome re-duplication assay using mimosine (600 mM) as described in (b). The centrosome profiles of the GFP-positive cells were determined by immunostaining with anti-g-tubulin antibody, and shown in the graph as average7standard error from three experiments. In each experiment, >200 cells were examined. As internal controls, untransfected p53 À/À MEFs before and after mimosine-treatment were included in the analysis.
suppressed centrosome re-duplication as effectively as wild-type p53 (column 8). Thus, both transactivation function and centrosome binding are required for p53 to maximally regulate centrosome duplication.
Even though numerous studies showing the centrosomal localization of p53, it had been unclear whether the centrosomally localized p53 has any role in the regulation of centrosome duplication. We have recently shown that mortalin, a member of hsp70 family and p53-binding protein (Wadhwa et al., 1998) , promotes dissociation of p53 from centrosomes (and prevents p53 from localizing to centrosomes) through physical interaction (Ma et al., 2006) . The p53 mutant deleted for the mortalin-binding sequence (a.a. 253-282) (Kaul et al., 2001) , which lacks its transactivation function, remains at centrosomes, and is able to suppress centrosome duplication (Ma et al., 2006) . Although this observation implies the transactivation-function-independent regulation of centrosome duplication by p53 localized at centrosomes, it is clearly far from demonstrating the role of centrosomally localized p53 in the regulation of centrosome duplication. In this study, we generated the p53 missense mutants that lost transactivation function and/or centrosome-binding activity, and tested these mutants for their activities to control centrosome duplication. Both the transactivation( þ )/centrosomebinding(À) and transactivation(À)/centrosomebinding( þ ) mutants could only partially suppressed centrosome duplication compared with wild-type p53. However, coexpression of the transactivation( þ )/centrosome-binding(À) and transactivation(À)/centrosome-binding( þ ) mutants suppressed centrosome duplication as effectively as wild-type p53. Moreover, the transactivation(À)/centrosome-binding(À) double mutant almost completely lost its ability to suppress centrosome duplication. These observations provide direct evidence for the transactivation-function-independent role of centrosomally localized p53 in the regulation of centrosome duplication in addition to its transactivation-function-dependent regulation. The molecular mechanism of how centrosomally localized p53 regulate centrosome duplication is not known at present, but identification of centrosomal protein(s) that interact with p53 will certainly shed a light on this issue.
It has been shown that B15% of the p53 mutations found in cancers (i.e., BRCA1-and BRCA2-associated p53 mutants, Ref. Smith et al., 1999) retain the transactivation function, which is indistinguishable from wild-type p53 (Campomenosi et al., 2001) , pointing to the transactivation function-independent tumor suppressor activity of p53. Abnormal amplification of centrosomes increases the frequency of mitotic defects and chromosome segregation errors, which accelerates tumor progression. Our finding that centrosomally localized p53 participates in the regulation of centrosome duplication suggests that the transactivationfunction-independent tumor suppressor activity of p53 may be the regulation of centrosome duplication by the centrosomally localized p53. In this context, it is of great interest to examine the centrosome-binding activities of the transactivation function positive p53 mutants found in cancer, which is currently under investigation in our laboratory.
